Skip to main content

What the FDA labels say about taking them together

Glucagon and lanreotide

Lanreotide's FDA label of October 11, 2024 names glucagon in its drug interactions section; the glucagon labels PlainMeds reads (4) do not name lanreotide.

Check it at the source: the glucagon FDA label on DailyMed (effective August 11, 2026, Amphastar Pharmaceuticals, Inc.); the lanreotide FDA label on DailyMed (effective October 11, 2024, Ipsen Biopharmaceuticals, Inc.).

What does the glucagon label say about lanreotide?

Glucagon's label (effective August 11, 2026) and its 3 other brand-application labels do not name lanreotide in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Glucagon), Amphastar Pharmaceuticals, Inc., effective August 11, 2026 (SPL set 8cc40354-b5ac-45b6-a211-93b44444f2a3), via openFDA; the full label on DailyMed

What does the lanreotide label say about glucagon?

Lanreotide label, drug interactions

Insulin and Oral Hypoglycemic Drugs Lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon.

Lanreotide label, warnings and precautions

Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon.

Source: FDA drug label (SOMATULINE DEPOT), Ipsen Biopharmaceuticals, Inc., effective October 11, 2024 (SPL set 6e4a41fd-a753-4362-87ee-8cc56ed3660d), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

6Glucagon generic labelers
3Lanreotide generic labelers
GlucagonLanreotide
Labeled forn/an/a
Boxed warningNoNo
Pharmacy cost (NADAC)$154.20 per kit 1 mg emergency kitn/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?